Osteoporosis
25 drugs49,133 FAERS reportsMedDRA PT
GET
/api/v1/reaction/osteoporosisReference statistics only. FAERS reports are voluntarily submitted and are not incidence rates, safety signals, or causal evidence. The drugs below are ranked by how often this reaction appears on FAERS reports for each drug — high share does not mean the drug caused the reaction, and absence from this list does not mean the reaction never occurred. This is not a symptom checker.
DefinitionNLM MeSH D015663
Metabolic disorder associated with fractures of the femoral neck, vertebrae, and distal forearm. It occurs commonly in women within 15-20 years after menopause, and is caused by factors associated with menopause including estrogen deficiency.
Source: U.S. National Library of Medicine — MeSH (Osteoporosis, Postmenopausal)
Drugs reporting Osteoporosis (25)
Share = reports listing this reaction ÷ total matched reports for the drug. — means the upstream totals query failed at ingest and the denominator is unknown.
- 1Elvitegravir2,89818%
- 2Cobicistat3,36216%
- 3Tenofovir Alafenamide6,03514%
- 4Cholecalciferol43414%
- 5Tenofovir Disoproxil9,19913%
- 6Adefovir15412%
- 7Emtricitabine9,03712%
- 8Lutein411%
- 9Tenofovir9,83911%
- 10Pantothenate410%
- 11Spongia Tosta39.4%
- 12Rilpivirine1,8707.7%
- 13Nelfinavir1376.6%
- 14Darunavir9274.9%
- 15Bismuth Subsalicylate2394.2%
- 16Dolutegravir7363.8%
- 17Podofilox43.7%
- 18Crofelemer83.5%
- 19Lopinavir4003.0%
- 20Doravirine302.9%
- 21Etravirine1262.9%
- 22Calcitonin882.8%
- 23Atazanavir4032.8%
- 24Raltegravir4302.6%
- 25Bictegravir2,766—
Related reactions
Other reactions most often co-reported on the same drug set. Ranked by Jaccard similarity over drug-id sets — pure data-derived co-occurrence, not a clinical relationship.
Literature
Recent PubMed references pinned to Osteoporosis, Postmenopausal as a MeSH major topic. About the reaction term itself — not about any specific drug.
- Weak bones, strong obsessions: a controlled study on Orthorexia nervosa, body image, and mood in postmenopausal osteoporosis.Archives of osteoporosis · 2026 · Şi̇ri̇n Ahısha B, Kalaoğlu E, Uyanık Kesmez T, et al.PMID 42183951DOI 10.1007/s11657-026-01719-4
- MMP14 Silencing Alleviates Inflammation-Associated Bone Loss in Chronic Periodontitis and Postmenopausal Osteoporosis in Association With Reduced JAK2/STAT3 Signaling.FASEB journal : official publication of the Federation of American Societies for Experimental Biology · 2026 · Jiang X, Jia W, Ma Q, et al.PMID 42159331DOI 10.1096/fj.202600092RR
- Macrophage polarization regulates bone homeostasis: a potential etiology and therapy for postmenopausal osteoporosis.Frontiers in immunology · 2026 · Danzeng Q, Wu F, Cui M, et al.PMID 42148148DOI 10.3389/fimmu.2026.1826988
- The Importance of Exercise Habits for Preventing Osteoporosis in Postmenopausal Women: Insights From the COVID-19 Pandemic.Journal of orthopaedic research : official publication of the Orthopaedic Research Society · 2026 · Shinohara I, Kusunose M, Nishimoto H, et al.PMID 42141925DOI 10.1002/jor.70225
- Dendrobine promotes osteogenesis-angiogenesis in postmenopausal osteoporosis by inhibiting Hippo signaling pathway.Journal of molecular histology · 2026 · Meng X, Chen X, Huang J, et al.PMID 42126726DOI 10.1007/s10735-026-10826-y
- Sulfation Attenuates Mitigating Effects of 25-Hydroxycholesterol on Postmenopausal Bone Loss.FASEB journal : official publication of the Federation of American Societies for Experimental Biology · 2026 · Liu H, Ma W, Niu Y, et al.PMID 42117615DOI 10.1096/fj.202600557R
Note. FAERS reports are voluntarily submitted and are NOT incidence rates, signals, or causal evidence. Counts reflect reporting volume, not how often a reaction occurs. Reference statistics only.